Skip to main content

Table 2 Treatment and survival outcome

From: Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East

Variable Total patients Percentage
Initial treatment
 Chemotherapy 100 50
 Radiotherapya 13 6.5
 Surgery alone 16 8
 Chemotherapy + Radiotherapy 68 34
 Rituximab alone 2 1
 Refused / No show 1 0.5
Type of chemotherapy
 ABVDb 147 73.5
 ABVD/ABV with COPP like 3 1.5
 COPPb 5 2.5
 R-CHOPc 11 5.5
 Othersd 6 3
Number of initial chemo cycle
 2 cycles a 31 15.5
 3 cycles 11 5.5
 4 cycles 64 32
 6 cycles a 53 26.5
 8 cycles 11 5.5
Response after initial treatment
 CR 164 82
 PR 11 5.5
 PDb 21 11.5
 On treatment 1 0.5
Tissue confirmation at Rx failure
 Type of first event 200 100
  No event 124 62
  Persistent disease 12 6
  Progressive disease 21 10.5
  Relapsed disease 36 18
  Treatment related mortality 1 0.5
  Death other causes 1 0.5
  Unknown 5 2.5
 Disease status at last visit
  Alive in remission 176 88
  Alive with disease 4 2
  Alive unknown status 1 0.5
  Lost to follow up 6 3
  On treatment 2 1
  Died of disease 8 4
  Died of other causec 3 1.5
High grade transformation 11 5.5
HDC auto-SCT 29 14.5
  1. Abbreviations: ABVD Adriamycin, bleomycin, vinblastin and dacarbazine, COPP/MOPP Cyclophosphamide / mechlorethamine, vincristine, procarbazine, prednisone, PR partial response
  2. a Rituximab × 4 before /or after radiotherapy in 2 patient, b Rituximab + ABVD in 9, Rituximab + COPP in 3, c Rituximab + CVP in 2, d Rituximab alone (3), rituximab + gemcitabine (1), dexamethasone, Ara-C, cisplatin (1), unknown at other institution (1). a 1 cycle in 2, 5 cycles in 4, b2 patients with no response (NR) or stable disease (SD) in this group, progressive disease (PD), complete remission (CR), complete remission unconfirmed (CRu), ctreatment related mortality in 2 (both with lung toxicity after R-ABVD, both in CR (1 for relapsed disease after radiation therapy). 1 patient with sickle cell related sever cardiomyopathy, died in CR
\